IN8bio Past Earnings Performance

Past criteria checks 0/6

IN8bio's earnings have been declining at an average annual rate of -35.5%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-35.5%

Earnings growth rate

45.4%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-234.6%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How IN8bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6JH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-321418
31 Mar 240-311417
31 Dec 230-301417
30 Sep 230-301416
30 Jun 230-301417
31 Mar 230-301416
31 Dec 220-291414
30 Sep 220-271413
30 Jun 220-231310
31 Mar 220-18108
31 Dec 210-1577
30 Sep 210-1256
30 Jun 210-1146
31 Mar 210-1146
31 Dec 200-1035
30 Sep 200-935
30 Jun 200-834
31 Mar 200-633
31 Dec 190-632

Quality Earnings: 6JH is currently unprofitable.

Growing Profit Margin: 6JH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6JH is unprofitable, and losses have increased over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare 6JH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6JH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: 6JH has a negative Return on Equity (-234.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies